Antibodies against canine PD-1
The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
1. An isolated mammalian antibody or the antigen binding fragment thereof that binds PD-1 comprising three light chain complementary determining regions (CDRs): CDR light 1 (CDRL1), CDR light 2 (CDRL2), and CDR light 3 (CDRL3); and three heavy chain CDRs: CDR heavy 1 (CDRH1), CDR heavy 2 (CDRH2) and CDR heavy 3 (CDRH3);
(a) wherein CDRL1 comprises the amino acid sequence of SEQ ID NO: 15;
(b) wherein CDRL2 comprises the amino acid sequence of SEQ ID NO: 18;
(c) wherein CDRL3 comprises the amino acid sequence of SEQ ID NO: 24;
(d) wherein CDRH1 comprises the amino acid sequence of SEQ ID NO: 29;
(e) wherein CDRH2 comprises the amino acid sequence of SEQ ID NO: 33; and
(f) wherein CDRH3 comprises the amino acid sequence of SEQ ID NO: 38.
2. The isolated mammalian antibody or antigen binding fragment thereof of claim 1 , wherein the mammalian antibody is a murine antibody.
3. The isolated mammalian antibody or antigen binding fragment thereof of claim 1 , that is a caninized antibody.
4. A pharmaceutical composition comprising the antibody or antigen binding fragment thereof of claim 3 , or antigen binding fragment thereof and a pharmaceutically acceptable carrier or diluent.
5. A method of increasing the activity of an immune cell, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 4 .